The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

Masimo (NASDAQ ... and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products.

Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price target of ...

The company has discontinued several projects, including noninvasive monitoring of cancer, bilirubin, and diabetes, due to lack of expected progress. Masimo Corp (NASDAQ:MASI) is experiencing ...